Trial Profile

Efficacy and tolerability of switching to telmisartan/amlodipine in patients with uncontrolled hypertension on RAS inhibitor monotherapy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 May 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amlodipine/telmisartan (Primary)
Indications Hypertension
Focus Therapeutic Use
Acronyms TEAMSTA Switch
Sponsors Boehringer Ingelheim

Most Recent Events

01 May 2012 New trial record
29 Apr 2012 Results presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension (ESH), according to a Boehringer Ingelheim media release.
29 Apr 2012 Results published in a Boehringer Ingelheim media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com